First-of-its-Kind Atrial Flow Regulator (AFR) Introduced for Pulmonary Arterial Hypertension

Occlutech introduces the first-of-its-kind Atrial Flow Regulator (AFR) easily implantable device designed for the treatment of Pulmonary Arterial Hypertension (PAH).

The AFR device particularly lowers the blood pressure in the heart. The AFR device is placed in the septum by creating a restrictive atrial septal opening by retaining the correct shape of a built-in shunt, thereby lowering the risk of intracardiac pressure and improving the heart's function.

People suffering from PAH may have symptoms such as shortness of breath, dizziness, and fatigue. People affected with PAH may experience a change in cells resulting in damages to the lung arteries.

These symptoms cause serious problems and negatively affect the quality of life. Ultimately, the right ventricle enlarges to hold more blood and the additional strain gradually causes the heart to fail.

US Food and Drug Administration (FDA) granted Breakthrough Device designation for first-in-class, implantable Atrial Flow Regulator (AFR) for the treatment of Pulmonary Arterial Hypertension (PAH).